• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022
Slide
previous arrow
next arrow

We focus on

+10 therapeutic areas

We study

+50 diseases

We commercialize in

+35 countries

Message from the Director General

“We have been able to motivate young people to become what we have become. We had the opportunity to work with a very committed generation, and we have a duty to follow that example.”

PhD. Marta Ayala Ávila

General Director

Our studies focus on

Research areas

Biomedicine

Research and development of vaccines and biopharmaceuticals for the diagnosis, treatment and prevention of diseases.

Read more
Animal Biotechnology

Research and development of biomolecules, vaccines and diagnostics to veterinary medicine and aquatic organisms.

Read more
Plant biotechnology

Genetic transformation of plants and development of diagnostic systems for the control of pests and phytopathogens.

Read more
Industrial Enzymes

Agricultural biotechnology is applied to the design of industrial enzymes, with impact on the quality and production of...

Read more
Why CIGB?

We are challenged to achieve high added value innovative products
that generate a positive impact on human, animal and plant health, as well as industrial productions, in harmony with the environment, to contribute to the socioeconomic development of Cuba
Top-tier productive scientific complex

that develops vaccines, drugs and diagnostics for human, animals and plants

COVID-19 vaccines and products

Novel and traditional that are used in Cuban treatment protocols for COVID-19, such as the Abdala vaccine. Cuba deploys mass vaccination of its population with its own vaccines.

Food sustainability

of the nation is prioritized through own scientific solutions that raise productive performance

Our directives

Marta Ayala Ávila, PhD

General Director

Vicedirector
Jorge Valdés Hernández, PhD

Deputy Director General

Yassel Ramos Gómez, PhD

Deputy director

Luis Javier González López, PhD

Director of Biomedical Research

Mario Pablo Estrada García, PhD

Director of Agricultural Research

Jorge Castro Velazco, PhD

Director of Preclinical Research and Animal Experimentation

Julio Esmir Baldomero Hernández, PhD

Director of Clinical Research

Ania Cabrales Rico, PhD

Director of Technological Development

MSc. Mabel Izquierdo López

Director of Quality Control

Ing. Jorge Luis Vega Elias

Production Director

Ing. Miriela Gil Mena

International Sales Director

Miladys Limonta Fernández, PhD

Director of Business Development

MSc. Yai Cruz Ruiseco

Director of Imports

See all

Heberprot-P®

First-in-class: only therapy for the effective healing of DFU and complex wounds

See Product
Results

Treatment with Heberprot-P®

Lesion covered by granulation tissue
83.9%
With complete closure of the lesion
46.2%
Non-amputee patients
71%
Upcoming events

Where you can know our results

BioNCiD 2027
23 May, 2027 27 May, 2027
INVITATION On behalf of the Organizing Committee, we are pleased to invite you register...
Read more

See all

We work for one health

We offer + 25 products

Our products are preventive, therapeutic or diagnostic. We design products first and only of its kind for diseases that have no other effective therapeutic solutions.

See all

Polyclonal antibodies

Polyclonal antibodies

Enzimes

HeberZima Taq ADN Polimerase

COVID-19

Abdala ST

Monoclonal antibodies

Monoclonal antibodies

Recombinant proteins

Recombinant proteins

Enzimes

HeberZima Pwo ADN Polimerase

Animal products

HeberFast Line® Gavac

COVID-19

Abdala

Biological reagent

Hemerubin

Antibodies conjugated to peroxidase

Antibodies conjugated to peroxidase

COVID-19

Mambisa

Biopharmaceutical products

Nasalferon

Biopharmaceutical products

Jusvinza

Biopharmaceutical products

Heberprot-P®

Biopharmaceutical products

HeberFERON®

Biopharmaceutical products

Heberon® Alfa R

Biopharmaceutical products

Hebervital®

Biopharmaceutical products

HeberNasvac®

Biopharmaceutical products

Proctokinasa®

Vaccines

Heberpenta®-L

Vaccines

Heberbiovac HB®

Vaccines

Quimi-Hib®

Biopharmaceutical products

Hebertrans®

Biopharmaceutical products

Heberkinasa®

Biopharmaceutical products

Hebermin®

Diagnostic tests

HeberFast Line® MaterniTest II

Diagnostic tests

HeberFast Line® Embarazo II

Diagnostic tests

HeberFast Line® anti-transglutaminasa

Diagnostic tests

HeberFast Line® Rotavirus

Animal products

Gavac®

Animal products

Porvac®

Animal products

Acuabio V®

Plant products

HeberNem®
What do we work on?

Main processes

RESEARCH
We cover biomedical, agricultural, preclinical and clinical research.
TECHNOLOGICAL DEVELOPMENT
We develop bio-products through genetic engineering and biotechnology techniques.
PRODUCTION
We design, produce, control and ensure the quality of biopharmaceutical products.
COMMERCIALIZATION
We guarantee the export of goods and the positioning of our products in the target markets.
News

Last news

Speech by the Director General at the Central Ceremony for the 40th Anniversary of the Center for Genetic Engineering and Biotechnology
75 Views
Nasalferon: health registration for the prophylaxis and treatment of viral respiratory infections
95 Views
Jusvinza represents a very important hope for the health of the Cuban people
91 Views

See all